Innovating Antibody Therapeutics: How GenScript Enhances Bispecific and TCE Development with Live Q&A

The rapid advancements in cancer immunotherapy have positioned bispecific antibodies (BsAbs) and T-cell engagers (TCEs) as transformative therapeutic strategies. However, the development of these complex molecules presents unique challenges, from selecting optimal formats to ensuring stability, efficacy, and manufacturability.

In this session, we will explore the latest innovations from GenScript for BsAb development, including novel formats and AI/ML-driven optimization. We will also highlight comprehensive solutions- ranging from gene synthesis and antibody engineering to high-throughput screening and developability assessment- can accelerate the discovery and optimization of these next-generation therapies.

Join us to learn how an integrated approach to antibody development can overcome key obstacles, streamline workflows, and enhance the success rate of novel immunotherapies.

Learning Objectives: 

1. Learn the basics of bispecific antibodies and how they function in cancer immunotherapy.

2. Gain insights to key development steps, including gene synthesis, antibody generation, and optimization.

3. Discover how GenScript's integrated solutions for high throughput screening, developability assessment, and custom protein production can streamline development.